Advertisement

Taking action: European Atherosclerosis Society targets the United Nations Sustainable Development Goals 2030 agenda to fight atherosclerotic cardiovascular disease in Europe

      In 2015, the United Nations launched the Sustainable Development Goals 2030 Agenda as a universal call to action to end poverty, protect the planet, and improve the lives and prospects for all [
      The sustainable development Agenda.
      ]. The 17 goals of this Agenda, adopted by all United Nations (UN) member states, are to be delivered within 15 years. As only 10 years remain, accelerated action is needed, with world leaders calling for a Decade of Action in 2019 to achieve these goals. According to the UN Secretary-General, urgent action is needed on three levels: 1) globally, to secure greater leadership, more resources and smarter solutions; 2) locally, to ensure smooth transition in policies, budgets, institutions and regulatory frameworks of governments, cities and local authorities; and 3) societally, to ensure an unstoppable movement of change by targeting all stakeholders. In accordance with its mission, the European Atherosclerosis Society (EAS) has committed itself to the Sustainable Development Goals 2030 Agenda and will act on all three levels.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. The sustainable development Agenda.
        (Available at)
        • Murray C.J.L.
        • Lopez A.D.
        Measuring the global burden of disease.
        N. Engl. J. Med. 2013; 369: 448-457
        • Murray C.J.L.
        • Lopez A.D.
        Measuring global health: motivation and evolution of the global burden of disease study.
        Lancet. 2017; 390: 1460-1464
        • Global Burden of Disease Study
        Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017.
        Lancet. 2018; 392: 1736-1788
        • Roth G.A.
        • Mensah G.A.
        • Johnson C.O.
        • Addolorato G.
        • Ammirati E.
        • Baddour L.M.
        • et al.
        Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 Study.
        J. Am. Coll. Cardiol. 2020; 76: 2982-3021
        • Yusuf S.
        • Reddy S.
        • Ôunpuu S.
        • Anand S.
        Global burden of cardiovascular diseases.
        Circulation. 2001; 104: 2746-2753
        • Moran A.E.
        • Roth G.A.
        • Narula J.
        • Mensah G.A.
        Global cardiovascular disease atlas.
        Glob Heart. 2014; 9: 3-16
        • Bae S.
        • Kim S.R.
        • Kim M.N.
        • Shim W.J.
        • Park S.M.
        Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis.
        Heart. 2020; https://doi.org/10.1136/heartjnl-2020-317901
        • Afshin A.P.
        • Sur J.
        • Fay K.R.
        • Cornaby L.
        • Ferrara G.
        • Salama G.S.
        • et al.
        Health effects of dietary risks in 195 countries, 1990,2013;2017: a systematic analysis for the Global Burden of Disease Study 2017.
        Lancet. 2019; 393: 1958-1972
        • Fullman N.
        • Yearwood J.
        • Abay S.M.
        • Abbafati C.
        • Abd-Allah F.
        • Abdela J.
        • et al.
        Measuring performance on the healthcare access and quality index for 195 countries and territories and selected subnational locations: a systematic analysis from the global burden of disease study 2016.
        Lancet. 2018; 391: 2236-2271
        • Gilmore A.B.
        • Fooks G.
        • Drope J.
        • Bialous S.A.
        • Jackson R.R.
        Exposing and addressing tobacco industry conduct in low-income and middle-income countries.
        Lancet. 2015; 385: 1029-1043
        • Mach F.
        • Baigent C.
        • Catapano A.L.
        • Koskinas K.C.
        • Casula M.
        • Badimon L.
        • et al.
        ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
        Eur. Heart J. 2019; 41: 111-188
        • Vartiainen E.
        The north karelia project: cardiovascular disease prevention in Finland.
        Glob Cardiol Sci Pract. 2018; 2018: 13
        • Timmis A.N.
        • Townsend C.P.
        • Gale A.
        • Torbica M.
        • Lettino S.E.
        • Petersen E.A.
        • et al.
        Cardiovascular disease statistics 2019.
        Eur. Heart J. 2019; 41: 12-85
        • World Health Organization data and statistics
        Health 2020 indicators: Tobacco smoking.
        • World Health Organization data and statistics
        Non-communicable diseases: risk factors. Blood pressure.
        (Cholesterol: https://apps.who.int/gho/data/node.main.A887?lang=en; Overweight/Obesity)
        • World Health Organization data and statistics
        Non-communicable diseases: Prevalence of diabetes mellitus.
        • Hay S.I.
        • Abajobir A.A.
        • Abate K.H.
        • Abbafati C.
        • Abbas K.M.
        • Abd-Allah F.
        • et al.
        Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.
        Lancet. 2017; 390: 1260-1344
        • Global Burden of Disease Study
        Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
        Lancet. 2018; 392: 1923-1994
        • Stanaway J.D.
        • Afshin A.
        • Gakidou E.
        • Lim S.S.
        • Abate D.
        • Abate K.H.
        • et al.
        Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
        Lancet. 2018; 392: 1923-1994
      2. WHO Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013–2020. World Health Organization, Geneva2013
        • Khatib R.
        • McKee M.
        • Shannon H.
        • Chow C.
        • Rangarajan S.
        • Teo K.
        • et al.
        Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data.
        Lancet. 2016; 387: 61-69
        • Murphy A.
        • Palafox B.
        • O'Donnell O.
        • Stuckler D.
        • Perel P.
        • AlHabib K.F.
        • et al.
        Inequalities in the use of secondary prevention of cardiovascular disease by socioeconomic status: evidence from the PURE observational study.
        Lancet Glob Health. 2018; 6: e292-e301
        • Yusuf S.
        • Joseph P.
        • Dans A.
        • Gao P.
        • Teo K.
        • Xavier D.
        • et al.
        Polypill with or without aspirin in persons without cardiovascular disease.
        N. Engl. J. Med. 2021; 384: 216-228
        • Roshandel G.
        • Khoshnia M.
        • Poustchi H.
        • Hemming K.
        • Kamangar F.
        • Gharavi A.
        • et al.
        Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
        Lancet. 2019; 394: 672-683
        • Muñoz D.
        • Uzoije P.
        • Reynolds C.
        • Miller R.
        • Walkley D.
        • Pappalardo S.
        • et al.
        Polypill for cardiovascular disease prevention in an underserved population.
        N. Engl. J. Med. 2019; 381: 1114-1123
        • Yusuf S.
        • Joseph P.
        • Dans A.
        • Gao P.
        • Teo K.
        • Xavier D.
        • et al.
        Polypill with or without aspirin in persons without cardiovascular disease.
        N. Engl. J. Med. 2021; 384: 216-228
        • Ference B.A.
        • Bhatt D.L.
        • Catapano A.L.
        • Packard C.J.
        • Graham I.
        • Kaptoge S.
        • et al.
        Association of genetic variants related to combined exposure to lower low-density lipoproteins and lower systolic blood pressure with lifetime risk of cardiovascular disease.
        J. Am. Med. Assoc. 2019; 322: 1381-1391
        • Brandts J.
        • Ray K.K.
        Low density lipoprotein cholesterol-lowering strategies and population health: time to move to a cumulative exposure model.
        Circulation. 2020; 141: 873-876
        • Ray K.K.
        • Stoekenbroek R.M.
        • Kallend D.
        • Nishikido T.
        • Leiter L.A.
        • Landmesser U.
        • Wright R.S.
        • Wijngaard P.L.J.
        • Kastelein J.J.P.
        Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial.
        JAMA Cardiol. 2019; 4: 1067-1075
        • Borén J.
        • Chapman M.J.
        • Krauss R.M.
        • Packard C.J.
        • Bentzon J.F.
        • Binder C.J.
        • et al.
        Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel.
        Eur. Heart J. 2020; 41: 2313-2330
        • Wilemon K.A.
        • Patel J.
        • Aguilar-Salinas C.
        • Ahmed C.D.
        • Alkhnifsawi M.
        • Almahmeed W.
        • et al.
        Reducing the clinical and public health burden of familial hypercholesterolemia: a global call to action.
        JAMA Cardiol. 2020; 5: 217-229
        • Vallejo-Vaz A.J.
        • Akram A.
        • Kondapally Seshasai S.R.
        • Cole D.
        • Watts G.F.
        • Hovingh G.K.
        • et al.
        • EAS Familial Hypercholesterolaemia Studies Collaboration
        Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration.
        Atherosclerosis Suppl. 2016; 22: 1-32